EXMceuticals (XCNQ:EXM) Debt-to-Asset : 0.83 (As of Mar. 2021)

View and export this data going back to 2010. Start your Free Trial

What is EXMceuticals Debt-to-Asset?

EXMceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was C$1.03 Mil. EXMceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was C$0.02 Mil. EXMceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2021 was C$1.27 Mil. EXMceuticals's debt to asset for the quarter that ended in Mar. 2021 was 0.83.

EXMceuticals Debt-to-Asset Historical Data

The historical data trend for EXMceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EXMceuticals Debt-to-Asset Chart

EXMceuticals Annual Data

Trend

Jun11

Jun12

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Debt-to-Asset

Get a 7-Day Free Trial

0.17

3.92

EXMceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Debt-to-Asset	Get a 7-Day Free Trial															1.80	3.92	0.40	0.55	0.83

Competitive Comparison of EXMceuticals's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, EXMceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EXMceuticals's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EXMceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where EXMceuticals's Debt-to-Asset falls into.

EXMceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

EXMceuticals's Debt-to-Asset for the fiscal year that ended in Jun. 2020 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(4.593	+	0.31)	/	1.252
	=	3.92

EXMceuticals's Debt-to-Asset for the quarter that ended in Mar. 2021 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.028	+	0.021)	/	1.268
	=	0.83

EXMceuticals (XCNQ:EXM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

EXMceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of EXMceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

EXMceuticals (XCNQ:EXM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EXMceuticals Inc (XCNQ:EXM) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

421 7th Avenue S.W., 30th Floor, Calgary, AB, CAN, T2P 4K9

Website

http://www.exmceuticals.com

EXMceuticals Inc is a bio-science company that believes in the potential health and wellness benefits of hemp and cannabis. EXM is an emerging player in the market, with ambition and potential to become the suppliers of highest-grade cannabis ingredients. It is creating an industrial-scale, GMP, Pharmaceutical Grade Extraction and Refining facility inside the European Union, near Lisbon Portugal. It has an existing and licensed cannabis R&D facility and pilot refinery in Lisbon Portugal. EXM is targeting the B2B marketplace and will supply pure ingredients and API's to the pharmaceutical, medicinal and wellness industry.

Executives

John Anderson

Director, Senior Officer

EXMceuticals (XCNQ:EXM) Headlines

No Headlines